Matrix metalloproteinases (MMP): Determination of different forms by different techniques may require different preanalytical strategies [2]

Multiple Sclerosis

Volumn 13, Issue 4, 2007, Pages 561-562

  Fainardi, E ^a   Castellazzi, M ^a   Bellini, T ^a   Dallocchio, F ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BLOOD SAMPLING; CENTRIFUGATION; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; ENZYME SYNTHESIS; FREEZE THAWING; HUMAN; LETTER; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STORAGE TEMPERATURE; THROMBOCYTE ACTIVATION; ZYMOGRAPHY;

BLOOD SPECIMEN COLLECTION; HUMANS; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS; REPRODUCIBILITY OF RESULTS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 34249030881     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070897     Document Type: Letter

References (10)

1. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I et al. Cerebrospinal fluid and serum, levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 2006; 12: 294-301.
2. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003; 49: 339-40.
3. Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003; 49: 1956-57.
4. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005; 344: 147-49.
5. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 2005; 338: 294-98.
6. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005; 38: 410-14.
7. Shen JR, Fong TH, Lin CM, Shen MY, Chen TL, Chang Y et al. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in in vivo studies. Br J Pharmacol 2004; 143: 193-201.
8. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelets activation mediates aggregation. Nature 1997; 386: 616-19.
9. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. A Consensus Statement. Arch Neurol 2005; 62: 865-70.
10. Verspaget HW, Kuyvenhoven JP, van Hock B. Preanalytical conditions and circulating matrix metallo-proteinases. Transplantation 2005; 79: 745-46.